Production (Stage)
NLS Pharmaceutics AG
NLSP
$2.30
$0.2210.58%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 0.00% | -19.65% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 0.00% | -22.92% | |||
| Operating Income | 0.00% | 22.92% | |||
| Income Before Tax | 0.00% | 102.70% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 0.00% | 102.70% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 0.00% | 102.70% | |||
| EBIT | 0.00% | 22.92% | |||
| EBITDA | -0.09% | 22.85% | |||
| EPS Basic | 0.00% | 48.91% | |||
| Normalized Basic EPS | 0.00% | 57.00% | |||
| EPS Diluted | 0.00% | 48.91% | |||
| Normalized Diluted EPS | 0.00% | 57.00% | |||
| Average Basic Shares Outstanding | 0.00% | 94.34% | |||
| Average Diluted Shares Outstanding | 0.00% | 94.34% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||